The American Society for Pharmacology and Experimental Therapeutics encourages the presentation of symposia on timely topics at its meetings. Symposia are valuable for promoting scientific interchange and developing new concepts in a way that crystallizes thinking in particular areas. This particular format helps investigators keep abreast of developments in fields that may not be intimately related to their own major research interests. The Program Committee is responsible for selecting symposia to be included in meetings of the Society.

(1) Proposed Symposium Title:
Innate immunity and cardiovascular disease: unfolding the therapeutic potential of toll-like receptors

(2) Chair(s)
Name: R. Clinton Webb
Email: sample@sampleuniv.edu
Are you an ASPET member? □ Yes □ No (At least one chair must be an ASPET member.)

Name: Styliani Goulopoulou
Email: sample@sampleuniv.edu
Are you an ASPET member? □ Yes □ No (At least one chair must be an ASPET member.)

(3) Co-sponsored by what other Divisions: ISTCP

(4) Program Justification:
The discovery of toll-like receptor (TLR) function was awarded the 2011 Nobel Prize in Physiology or Medicine. TLRs are pattern recognition receptors (PRRs) that activate the innate immune response. In addition to exogenous infectious ligands (pathogen-associated molecular patterns, PAMPs), TLRs sense certain endogenous molecules (damage-associated molecular patterns, DAMPs) that are released during host tissue injury/death. Activation of TLRs by exogenous or endogenous ligands leads to the activation of NF-κB (nuclear factor κB) and the production of pro-inflammatory cytokines that may have both beneficial (i.e., repair) and detrimental (i.e., inflammation) effects on the host. TLRs are expressed in immune cells but also in cardiac and vascular tissues, suggesting that TLRs may be a link between innate immunity, inflammation, and cardiovascular disease. Recent studies provide evidence for the involvement of TLRs in stroke, hypertension, preeclampsia, myocardial infarction, heart failure, atherosclerosis, and myocarditis. The symposium deals with newly discovered TLR-associated molecular pathways that are involved in the genesis of endothelial dysfunction and cardiovascular remodelling characterizing various cardiovascular pathologies. The interaction between TLRs and other innate immune receptors in cardiovascular diseases will be considered and the therapeutic potential of TLR manipulation will be discussed.

(5) Format: Please note that in order to receive travel reimbursement, speakers must speak for a minimum of 20 minutes. If a speaker is also moderating a panel, or serving as a discussion group facilitator, the time for this activity may be included. Please describe the proposed format and note if any special room set up requested.

There will be four 20-minute presentations followed by a 5-minute discussion and three short-talks (10 minutes followed by a 5-minute discussion) chosen from abstracts.

<table>
<thead>
<tr>
<th>Length of Talk</th>
<th>Speaker Name</th>
<th>Talk Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 minutes</td>
<td>R.C. Webb</td>
<td>Introduction</td>
</tr>
<tr>
<td>20 minutes + 5 Q&amp;A</td>
<td>Bruce Beutler</td>
<td>TLR signaling: Innate immune sensing and response</td>
</tr>
<tr>
<td>20 minutes + 5 Q&amp;A</td>
<td>Polly Matzinger</td>
<td>&quot;Shall I respond?:&quot; DANGERous questions and answers</td>
</tr>
<tr>
<td>20 minutes + 5 Q&amp;A</td>
<td>Brett Mitchell, Ph.D.</td>
<td>Doubled-stranded RNA receptors in pregnancy-induced hypertension</td>
</tr>
<tr>
<td>20 minutes + 5 Q&amp;A</td>
<td>Claudia Monaco</td>
<td>TLRs: new therapeutic targets for treating atherosclerosis</td>
</tr>
<tr>
<td>45 minutes</td>
<td>TBD</td>
<td>3 short talks selected from abstracts</td>
</tr>
</tbody>
</table>

Total length should add up to 150 minutes including introductions, summaries and Q&A.
(6) Are you planning to have junior speakers participate in this symposium? Yes ☐ No ☐
Will the junior speakers be selected from submitted abstracts? Yes ☐ No ☐
If not from Submitted Abstracts, how will junior speakers be selected?

(7) Proposed Speakers Detail:

<table>
<thead>
<tr>
<th>Speaker Name</th>
<th>Degree(s)</th>
<th>Contact Information (Dept, Institution, Address, Phone, Email):</th>
<th>Description of Talk:</th>
</tr>
</thead>
</table>
| R.C. Webb    | PhD       | Address: University of Sample
Department of Pharmacology
1234 Main Street, Building 7
Augusta, GA 30912 | Provide overview of outcomes of the symposium and introduce speakers |
| Bruce Beutler| M.D.      | University of Sample
Department of Pharmacology
1234 Main Street, Building 7
La Jolla, CA 92037 | TLR signaling: Innate immune sensing and response |
| Polly Matzinger| PhD | University of Sample
Department of Pharmacology
1234 Main Street, Building 7
Bethesda, MD 20892 | “Shall I respond?”: DANGERous questions and answers |
**Speaker 4 Name:** Brett Mitchell, Ph.D.  
**Degree(s):**  
**Contact Information (Dept, Institution, Address, Phone, Email):**  
University of Sample  
Department of Pharmacology  
1234 Main Street, Building 7  
Temple, TX 76504  
Phone: (301) 555-1234  
Email: sample@sampleuniv.edu  
**Talk Title:** Doubled-stranded RNA receptors in pregnancy-induced hypertension  
**Description of Talk:** Invading pathogens and dead or necrotic tissue activate the maternal immune response during pregnancy. This talk will discuss the role of double-stranded RNA in the activation of innate immune receptors and the development of preeclampsia and pregnancy-induced hypertensive disorders.

---

**Speaker 5 Name:** Claudia Monaco  
**Degree(s):**  
**Contact Information (Dept, Institution, Address, Phone, Email):**  
University of Sample  
Department of Pharmacology  
(301) 555-1234; sample@sampleuniv.edu:  
**Talk Title:** TLRs: new therapeutic targets for treating atherosclerosis  
**Description of Talk:** TLRs are versatile molecular patterns that initiate innate immune signaling in atherosclerosis. This talk will discuss the versatile nature of TLRs achieved by TLR heterodimer formation and cooperation with co-receptors and binding proteins. Further, the involvement of TLRs signaling in the development of atherosclerosis and the potential of TLR antagonism in the treatment of atherosclerosis will be addressed.

---

**Chair 1 Name:** R. Clinton Webb  
**Degree(s):** PhD  
**Contact Information (Dept, Institution, Address, Phone, Email):**  
University of Sample  
Department of Pharmacology  
1234 Main Street, Building 7  
Augusta, GA 30912  
Phone: (301) 555-1234  
Email: sample@sampleuniv.edu

**Chair 2 Name:** Styliani Goulopoulou  
**Degree(s):** PhD  
**Contact Information (Dept, Institution, Address, Phone, Email):**  
University of Sample  
Department of Pharmacology  
1234 Main Street, Building 7  
Augusta, GA 30912  
Phone: (301) 555-1234  
Email: sample@sampleuniv.edu

---

(8) Alternate Speakers  
Please describe your plans for alternates if the speakers above are not available.  
Alternate for Bruce Beutler is Gregory Burton from UC-Berkeley  
Alternate for Polly Matzinger is Elizabeth Bonney from University of Vermont  
Alternate for Brett Mitchell is Vikki Abrahams from Yale  
Alternate for Claudia Monaco is Adam Mullick from Isis Pharmaceuticals  
Additionally the chairs are able to serve as alternates on any of topics.
(9) **Preliminary Financial Requirements**: Symposia are allocated a maximum of $4800 to help defray speaker travel expenses for speakers whose talks are at least 20 minutes. All speakers and chairs receive complimentary registration. Please note if this proposed symposium has other financial requirements.

All plans would fit within allocated $4800 budget.

Areas to Consider:
- Is there gender/ethnic/race/age diversity among your speakers?
- Do your speakers represent diverse sectors (i.e. government, industry, academia)?
- Is your topic cutting edge?
- Is your topic engaging to ASPET members as well as other Experimental Biology scientists?

Click Division Button below to submit form via email. You may submit to multiple divisions.

- Click Here for: Behavioral Pharmacology
- Click Here for: Cancer
- Click Here for: Cardiovascular Pharmacology
- Click Here for: Drug Discovery and Development
- Click Here for: Drug Metabolism
- Click Here for: Integrative Systems, Translational and Clinical Pharm.
- Click Here for: Molecular Pharmacology
- Click Here for: Neuropharmacology
- Click Here for: Pharmacology Education
- Click Here for: Toxicology
- Click Here for all OTHER topics